Drug Trial Radar · NCT02753946
Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections
Last checked: Nov 19, 2026Latest source record: Mar 7, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
465
Actual
Start
Apr 2016
Primary completion
Jan 12, 2017
Study completion May 30, 2017
Sponsor
- Lead sponsor
- Nabriva Therapeutics AGIndustry
- Sponsor type
- Industry
- Collaborators
- Medpace, Inc.
- First posted
- Apr 28, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to demonstrate the safety and efficacy of ZTI-01 (IV fosfomycin) as non-inferior to piperacillin/tazobactam in overall success (clinical cure and microbiologic eradication) for the treatment of hospitalized patients with complicated urinary tract infections (cUTI) or acute pyelonephritis (AP).
Conditions
- Urinary Tract Infection Symptomatic
- Acute Pyelonephritis
- Urinary Tract Infection Complicated
Interventions
ZTI-01Drug
6g ZTI-01 intravenous infusion TID q8 hours
Piperacillin-tazobactamDrug
4.5g piperacillin-tazobactam intravenous infusion TID q8 hours
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients With an Overall SuccessTime frame: TOC Visit (Day 19)
Locations
68 sites in 16 countries. Site status is shown where the registry gives one.
Site not named
Pensacola, Florida
Site not named
Augusta, Georgia
Site not named
Columbus, Georgia
Site not named
Boylston, Massachusetts
Site not named
St Louis, Missouri
Site not named
Butte, Montana
Site not named
Brest, Belarus
Site not named
Grodno, Belarus
Site not named
Homyel, Belarus
Site not named
Minsk, Belarus
Site not named
Vitebsk, Belarus
Site not named
Plovdiv, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Slavonski Brod, Croatia
Site not named
Split, Croatia
Site not named
Zagreb, Croatia
Site not named
Brno, Czechia
Site not named
Hradec Králové, Czechia
Site not named
Liberec, Czechia
Site not named
Kohtla-Järve, Estonia
Site not named
Tallinn, Estonia
Site not named
Batumi, Georgia
Site not named
Kutaisi, Georgia
Site not named
Tbilisi, Georgia
Site not named
Ampelokipoi, Greece
Site not named
Athens, Greece
Site not named
Thessaloniki, Greece
Site not named
Budapest, Hungary
Site not named
Miskolc, Hungary
Site not named
Nagykanizsa, Hungary
Site not named
Pécs, Hungary
Site not named
Szekszárd, Hungary
Site not named
Szentes, Hungary
Site not named
Riga, Latvia
Site not named
Valmiera, Latvia
Site not named
Kaunas, Lithuania
Site not named
Klaipėda, Lithuania
Site not named
Vilnius, Lithuania
Site not named
Bielsko-Biala, Poland
Site not named
Krakow, Poland
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.